Highlighted potential long-term benefits of INB-200. As of October 18, 2024, five patients remained alive, three patients had ...

Two physicians and Harvard Medical School professors sued the Trump administration for taking down peer reviewed articles ...

Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...